Follow our progress.

Milestones in our journey to reinvent genetic testing.

Back to full list

Press Releases

Invitae to Present at the UBS Global Healthcare Conference

Invitae to Present at the UBS Global Healthcare Conference

May 12, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer of Invitae, will present at the UBS Global Healthcare Conference on Monday, May 22, 2017 at 11:00 a.m. Eastern / 8:00 a.m. Pacific in New York City.

The live, listen-only webcast of the presentation may be accessed by visiting the Investors section of the company’s website at ir.invitae.com. A replay of the webcast will ...

Read more


Invitae Exceeds 26,000 Samples Accessioned, Reports Revenue of $10.3 Million and Net Loss of $0.64 Per Share in First Quarter 2017

Invitae Exceeds 26,000 Samples Accessioned, Reports Revenue of $10.3 Million and Net Loss of $0.64 Per Share in First Quarter 2017

May 08, 2017

Management expects full-year 2017 revenue between $55 million and $65 million

Hosting conference call at 4:30 pm ET / 1:30 pm PT

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the quarter ended March 31, 2017.

First Quarter 2017 Financial Highlights:

  • Generated revenue of $10.3 million in the first quarter of 2017, compared to $4.0 million in the first quarter of 2016.
  • Accessioned more than 26 ...

Read more


New research suggests current genetic testing guidelines may miss breast cancer patients who could benefit from testing

New research suggests current genetic testing guidelines may miss breast cancer patients who could benefit from testing

April 28, 2017

Broader use of genetic testing may better assess hereditary cancer risk in breast cancer patients and their families

 

New research suggests that current clinical guidelines on the use of genetic testing in breast cancer patients are too narrow and allow patients with pathogenic variants to be missed. The findings were presented at the American Society of Breast Surgeons (ASBS) Annual Meeting in Las Vegas, and come from a collaboration between TME Research, which represents more than 300 breast care practices ...

Read more


Invitae to Present at the Bank of America Merrill Lynch 2017 Health Care Conference

Invitae to Present at the Bank of America Merrill Lynch 2017 Health Care Conference

April 27, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer, will present at the Bank of America Merrill Lynch 2017 Health Care Conference on Thursday, May 18, 2017 at 10:40 a.m. Pacific in Las Vegas. Sean George will also participate in a panel discussion titled “Genetic Testing - Pricing, Payment and Policy in a Rapidly Growing Space” on Wednesday, May 17 at 4:20 p.m. Pacific.

The live ...

Read more


Invitae to Announce First Quarter 2017 Financial Results and Host Conference Call on May 8, 2017

Invitae to Announce First Quarter 2017 Financial Results and Host Conference Call on May 8, 2017

April 24, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its first quarter 2017 financial results on Monday, May 8, 2017 and will host a conference call that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments.

The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for ...

Read more


Invitae announces expansion of its genetic test menu with addition of new tests and expanded panels for inherited metabolic and immune system disorders, including panels to confirm diagnoses suggested by newborn screening

Invitae announces expansion of its genetic test menu with addition of new tests and expanded panels for inherited metabolic and immune system disorders, including panels to confirm diagnoses suggested by newborn screening

April 20, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced the addition of 80 new panels alongside updates to an additional 24 panels for the diagnosis of inherited immunologic and metabolic disorders, including panels designed to confirm diagnoses suggested by newborn screening. The new and updated tests further expand the company’s robust menu of high-quality, affordable diagnostic genetic tests available for use by clinicians.

Many inherited metabolic disorders, such as lysosomal storage disorders, are caused ...

Read more


Invitae expands its Genome Network with the launch of the Invitae Patient Insights Network (PIN), enabling participants to share health information and contribute to research

Invitae expands its Genome Network with the launch of the Invitae Patient Insights Network (PIN), enabling participants to share health information and contribute to research

April 06, 2017

A new approach to a patient registry, the Invitae PIN connects patients, clinicians, researchers, and biopharma therapeutics developers

Permission-based, patient-centric network designed to connect patients to potential treatments and accelerate scientific discovery

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced the launch of the Invitae Patient Insights Network‚Ą†, a permission-based, patient-centered network designed to make it easy for patients to share health experiences, contribute de-identified clinical data, and maintain their privacy while being connected ...

Read more


Invitae announces new partnership with Alnylam Pharmaceuticals to provide TTR gene testing for patients suspected of having hereditary ATTR amyloidosis

Invitae announces new partnership with Alnylam Pharmaceuticals to provide TTR gene testing for patients suspected of having hereditary ATTR amyloidosis

April 03, 2017

Offered through Invitae’s Genome Network, program drives early diagnosis to help patients and their clinicians make more informed decisions about their health

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, has announced a program in partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, to provide genetic testing for hereditary ATTR (hATTR) amyloidosis, a rare, progressive and life-threatening disease caused by a mutation in the TTR gene which causes accumulation of misfolded proteins in nerves ...

Read more


Invitae announces introduction of exome testing

Invitae announces introduction of exome testing

March 30, 2017

Exome testing expands company’s menu, offering an important tool for diagnosing a wide array of genetic disorders

Test menu now includes more than 20,000 genes

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced a major expansion of its genetic testing services with the introduction of exome sequencing and interpretation services, bringing the company’s available test menu to more than 20,000 genes. The Invitae Boosted Exome offers high-quality testing tailored to ...

Read more


Invitae Expands Test Menu for Proactive Genetic Testing in Healthy Adults

Invitae Expands Test Menu for Proactive Genetic Testing in Healthy Adults

March 23, 2017

Research outlining medically actionable approach, patient experiences in pilot program presented at American College of Medical Genetics Annual Clinical Genetics Meeting

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced it has expanded the menu of tests offered as part of its ongoing proactive genetic testing pilot program. The announcement was made during the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting in Phoenix, where Invitae researchers also presented findings from the company ...

Read more

  • Page 1 of 2
  • 1
  • 2

Invitae’s Mission

Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice in order to improve healthcare for billions of people. There are three stages to Invitae’s business model:

  1. Make genetic testing more affordable and accessible than ever before.
  2. Build a secure and trusted genome management infrastructure with which we help individuals manage their own genetic information over the course of their life.
  3. Design a genome network, a global community for sharing genetic information to advance science and medicine and allow patients, doctors and organizations to connect around genetic conditions.

Invitae’s four core principles

  1. Patients should own and control their own genetic information.
  2. Healthcare professionals are fundamental in ordering and interpreting genetic information.
  3. Driving down the price of genetic information will increase that information’s clinical and personal utility.
  4. Genetic information is more valuable when shared.

About Invitae

Invitae Corporation’s (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a diagnostic service comprising hundreds of genes for a variety of genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas.

For more information, visit out website at ir.invitae.com and follow us on Twitter: @invitae and @invitaeIR